Be part of the knowledge.™

Rare and Orphan Diseases

389

LikeLikedUnlike

Episodes 1-15 of 253

Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
- Ryan Quigley
  Peer
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Clinician's Roundtable
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Caterina Garone, MD, PhD
  Peer
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
Clinician's Roundtable
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Cristina Domínguez González, MD, PhD
  Peer
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Clinician's Roundtable
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Philip Yeske, PhD
  Peer
Advancing gMG Care: Conversations with Clinicians at AANEM
NeuroFrontiers
Advancing gMG Care: Conversations with Clinicians at AANEM
- Marlene Mimi Maeusli, PhD
  Peer
- Michael Weiss, MD
  Peer
- Joshua Alpers, MD
  Peer
- James F. Howard, Jr, MD
  Peer
- Omar Sinno, MD, MBA
  Peer
- Rodrigo Rodriguez, MD
  Peer
- Sheetal Shroff, MD
  Peer
Personalizing Treatment for gMG: On the Ground at AANEM
NeuroFrontiers
Personalizing Treatment for gMG: On the Ground at AANEM
- Marlene Mimi Maeusli, PhD.
  Peer
- Rodrigo Rodriguez, MD
  Peer
- Sheetal Shroff, MD
  Peer
- Joshua Alpers, MD
  Peer
advertisement
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiers
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
- Sheetal Shroff, MD
  Peer
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiers
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
- Michael Weiss, MD
  Peer
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiers
Individualizing gMG Treatment: Defining Success With Each Patient
- Omar Sinno, MD
  Peer
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Michael Wang, MD
  Peer
Managing Genotype-Positive Patients in Hereditary ATTR-CM
On the Frontlines of ATTR-CM
Managing Genotype-Positive Patients in Hereditary ATTR-CM
- Shelina Ramnarine, PhD
  Peer
- Naveen L. Pereira, MD
  Peer
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Project Oncology®
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
- Brian P. McDonough, MD, FAAFP
  Peer
- Doris M. Ponce, MD, MS
  Peer
advertisement
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiers
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiers
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiers
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
- Ryan Quigley
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended